TOTEM Switching the NRTI Backbone to Tenofovir DFEmtricitabine TOTEM Study Design Source Valantin MA et al J Antimicrob Chemother 20106555661 TDFFTC Continue 3 rd ID: 1014862
Download Presentation The PPT/PDF document "Switching the NRTI Backbone to Tenofovir..." is the property of its rightful owner. Permission is granted to download and print the materials on this web site for personal, non-commercial use only, and to display it on your personal computer provided you do not modify the materials and that you retain all copyright notices contained in the materials. By downloading content from our website, you accept the terms of this agreement.
1. Switching the NRTI Backbone to Tenofovir DF-EmtricitabineTOTEM
2. Switching the NRTI Backbone to Tenofovir DF-EmtricitabineTOTEM: Study DesignSource: Valantin MA, et al. J Antimicrob Chemother. 2010;65:556-61.TDF-FTC + Continue 3rd Agent(n = 46)Continue Current ART(n = 45)Study Design: TOTEMBackground: 12-week, multicenter, open-label, randomized trial of substituting the NRTI backbone with TDF-FTC for virologically suppressed patients with elevated lipidsInclusion Criteria (n = 91)- Adults with HIV infection- HIV RNA <400 copies/mL for >6 months- Elevated fasting LDL or triglycerides- Receiving 2 NRTI’s (not TDF-FTC) plus an NNRTI or boosted PITreatment Arms (Randomized 1:1)- Replace NRTI backbone with TDF-FTC- Continue current regimen
3. Switching the NRTI Backbone to Tenofovir DF-EmtricitabineTOTEM: ResultsWeek 12: Change in Plasma Lipids from Baseline Source: Valantin MA, et al. J Antimicrob Chemother. 2010;65:556-61.P < 0.001P = 0.031P = 0.009P = 0.034
4. Switching the NRTI Backbone to Tenofovir DF-EmtricitabineTOTEM: ResultsSource: Valantin MA, et al. J Antimicrob Chemother. 2010;65:556-61.Conclusions: “Switching to tenofovir disoproxil fumarate + emtricitabine in dyslipidaemic HIV-infected patients improves triglycerides and LDL-cholesterol.”
5.